Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totaling 188,339 shares, a decline of 73.0% from the July 15th total of 696,739 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.
Shanghai Junshi Biosciences Stock Performance
SHJBF stock opened at C$3.35 on Thursday. The company’s 50 day moving average price is C$3.35 and its 200 day moving average price is C$3.17. Shanghai Junshi Biosciences has a fifty-two week low of C$2.99 and a fifty-two week high of C$4.23.
About Shanghai Junshi Biosciences
Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.
Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.
See Also
- Five stocks we like better than Shanghai Junshi Biosciences
- Abercrombie’s Comeback Is a Work in Progress
- Roku’s Ad Business Is Growing—These 3 Stocks Could Be Next
- Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
- Voyager Technologies: Space Force Deal Fuels Growth Despite Heavy Cash Burn
Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
